Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 89-93

  Sun, Jong Mu ^a   Ahn, Jin Seok ^a   Lee, Soohyeon ^a   Kim, Jung A ^a   Lee, Jeeyun ^a   Park, Yeon Hee ^a   Park, Hee Chul ^a   Ahn, Myung Ju ^a   Ahn, Yong Chan ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Fracture; Non small cell lung cancer; Predictive factor; Skeletal related event; Spinal cord compression

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ERLOTINIB; GEFITINIB; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PATHOLOGIC FRACTURE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SPINAL CORD COMPRESSION; VERTEBRA FRACTURE;

BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 78650192661     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.04.003     Document Type: Article

References (26)

1. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
2. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
3. Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
4. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
5. Cook R.J., Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001, 93:534-538.
6. Major P.P., Cook R.J., Chen B.L., Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005, 2:234-240.
7. Cook R.J., Lawless J.F. Analysis of repeated events. Stat Meth Med Res 2002, 11:141-166.
8. Tsuya A., Kurata T., Tamura K., Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007, 57:229-232.
9. Delea T.E.M., McKiernan J.M.D., Brandman J.B.M.S., Edelsberg J.M.D.M.P.H., Sung J.P.M.S., Raut M.P., et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006, 1:571-576.
10. Hirsh V., Major P.P., Lipton A., Cook R.J., Langer C.J., Smith M.R., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236.
11. Wei L.J., Lin D.Y., Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989, 84:1065-1073.
12. Albain K.S., Elledge R., Gradishar W.J., Rowinsky D.F., Hudis E., Hayes C., et al. Open-label, phase II, multicenter trial of AD 1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002, 76:S33.
13. Lu X., Wang Q., Hu G., Van Poznak C., Fleisher M., Reiss M., et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009, 23:1882-1894.
14. Kim S.J., Uehara H., Karashima T., Shepherd D.L., Killion J.J., Fidler I.J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003, 9:1200-1210.
15. Zhu J., Jia X., Xiao G., Kang Y., Partridge N.C., Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007, 282:26656-26664.
16. Normanno N., Gullick W.J. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?. Endocr Relat Cancer 2006, 13:3-6.
17. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 2005, 12:471-482.
18. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008, 214:559-567.
19. Angelucci A., Gravina G.L., Rucci N., Millimaggi D., Festuccia C., Muzi P., et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006, 13:197-210.
20. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002, 62:2554-2560.
21. Trinkaus M., Simmons C., Myers J., Dranatisaris G., Clemons M. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 2009.
22. Brufsky A.M. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008, 13:187-195.
23. Ward K.D., Klesges R.C. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001, 68:259-270.
24. Williams A.R., Weiss N.S., Ure C.L., Ballard J., Daling J.R. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gynecol 1982, 60:695-699.
25. De Marinis F., Eberhardt W., Harper P.G., Sureda B.M., Nackaerts K., Soerensen J.B., et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009, 4:1280-1288.
26. Kim H.S., Park K., Jun H.J., Yi S.Y., Lee J., Ahn J.S., et al. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 2009, 76:239-246.